Ajay K. Nooka, MD, MPH, FACP

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (254 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Cancer Prevention and Control
Practicing Since

2011

Call 404-778-0519

Background

Ajay K. Nooka, MD, MPH, FACP, is a board certified hematologist specializing in the treatment of patients with multiple myeloma and plasma cell disorders.

Dr. Nooka serves as associate director of clinical research for Winship Cancer Institute of Emory University. In this role, he provides strategic oversight for all clinical research conducted at Winship, with a focus on supporting high-quality, safe and ethical research and ensuring that patients have equitable access to Winship’s innovative clinical trials. He also serves as scientific director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University and as director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Dr. Nooka is a clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University. He serves on the steering committee of the Multiple Myeloma Research Consortium.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Associate Director of Clinical Research

Winship Cancer Institute of Emory University
Director, Myeloma Program, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2011
Winship Cancer Institute
Residency, Internal Medicine, 2008
Canton Medical Education Foundation
Medical Education, MBBS, 2000
NTR University of Health Sciences/Andhra Medical College

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2011
Hematology
American Board of Internal Medicine, 2011
Internal Medicine
American Board of Internal Medicine, 2008

Research

Dr. Nooka's research interests include integrating genomic and clinical data on a uniform platform; interpreting data in a meaningful way to risk-stratify myeloma; and evaluating newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. He also focuses on cancer epidemiology.

View Current Clinical Trials


Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase I Conditions Relapsed Multiple Myeloma, Refractory Multiple Myeloma Location Winship Cancer Institute
A Study of Daratumumab Phase III Conditions Multiple Myeloma Location Winship Cancer Institute
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Phase II Conditions Plasma Cell Myeloma Location Winship Cancer Institute
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Phase III Conditions Multiple Myeloma Location Winship Cancer Institute
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy Phase N/A Conditions Plasma Cell Myeloma Location Winship Cancer Institute

Publications

Dr. Nooka serves on the editorial board for The American Journal of Clinical Oncology, Journal of Hematological Malignancies, Lymphoma and Chronic Lymphocytic Leukemias, and serves as section editor of hematologic malignancies for Cancer. He is an ad hoc journal reviewer for Annals of Oncology, Oncology, Leukemia Research, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, European Journal of Cancer, Current Oncology, Indian Journal of Medical Research and International Journal of Hematology.

Title/Journal	Authors	Publication Date
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. British journal of haematology	N Biran, B Dhakal, R Niesvizky, S Lentzsch, D Bhutani, JT McKay, DH Vesole, A Nooka, B Paul, PN Hari, S D'Ambrosi, R Kuiper, M van Vliet, D Siegel, SZ Usmani, F van Rhee	04/15/2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis. American journal of hematology	J Richter, A Nooka, P Rodríguez-Otero, F Schjesvold, E Katodritou, E Combe, M Scott, L Cooper, I Sly, N Ballew, J Bitetti, N Boytsov, M Purser, S McNamara	03/27/2025
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood	R Nair, AH Vu, AK Freer, KS Bhatia, D Wang, MR Savani, SM Matulis, S Lonial, DL Jaye, LH Boise, SY Seo, TW Corson, AK Nooka, S Bhatt, SK McBrayer, VA Gupta, X Hu, BG Barwick, AR Reddi, M Shanmugam	02/13/2025
Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood advances	SV Potdar, S Kapadia, MI Azeem, R Radzievski, K Lakhani, NS Joseph, JL Kaufman, CC Hofmeister, VA Gupta, S Lonial, AK Nooka, KM Dhodapkar, MV Dhodapkar	02/05/2025
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs. Acta haematologica	J Barberio, TL Lash, AK Nooka, AI Naimi, RE Patzer, C Kim	01/01/2025
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity. NPJ vaccines	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	10/27/2024
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study. Blood cancer journal	NWCJ van de Donk, N Bahlis, LJ Costa, MV Mateos, AK Nooka, A Perrot, AL Garfall, P Thaman, K Qi, C Uhlar, K Chastain, M Doyle, SZ Usmani	10/21/2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood cancer journal	NS Joseph, JL Kaufman, VA Gupta, CC Hofmeister, MV Dhodapkar, LH Boise, SM DiCamillo, D Roberts, AK Nooka, S Lonial	09/13/2024
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. The Lancet. Haematology	MK Khan, TH Nasti, JY Qian, TJ Kleber, JM Switchenko, JL Kaufman, AJ Nooka, MV Dhodapkar, ZS Buchwald, D Obiekwe, S Lonial, R Ahmed	07/01/2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British journal of haematology	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, TM Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PM Voorhees, SZ Usmani, PG Richardson	06/01/2024
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components. Blood advances	AP Wheeler, EL Snyder, M Refaai, CS Cohn, J Poisson, M Fontaine, M Sehl, AK Nooka, L Uhl, PC Spinella, M Fenelus, D Liles, T Coyle, J Becker, M Jeng, EA Gehrie, BR Spencer, P Young, A Johnson, JJ O'Brien, GJ Schiller, JD Roback, E Malynn, R Jackups, ST Avecilla, K Liu, S Bentow, J Varrone, RJ Benjamin, LM Corash	05/14/2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The Lancet. Oncology	P Rodriguez-Otero, S Usmani, AD Cohen, NWCJ van de Donk, X Leleu, J Gállego Pérez-Larraya, S Manier, AK Nooka, MV Mateos, H Einsele, M Minnema, M Cavo, BA Derman, N Puig, F Gay, PJ Ho, WJ Chng, E Kastritis, G Gahrton, K Weisel, C Nagarajan, F Schjesvold, J Mikhael, L Costa, NS Raje, E Zamagni, R Hájek, N Weinhold, K Yong, JC Ye, S Sidhana, G Merlini, T Martin, Y Lin, A Chari, R Popat, JL Kaufman	05/01/2024
Shrinking the divide: improving myeloma CART access. Blood advances	AK Nooka, MA Hartley-Brown, KC Anderson, S Lonial	01/09/2024
Glücksklee, the Quad, and High-Risk Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, JL Kaufman, S Lonial	01/01/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	12/20/2023
Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood cancer journal	M Bhutani, BJ Blue, C Cole, AZ Badros, SZ Usmani, AK Nooka, L Bernal-Mizrachi, J Mikhael	12/18/2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The oncologist	CS Lalonde, JM Switchenko, M Behera, MA Bilen, TK Owonikoko, JL Kaufman, AK Nooka, CM Lewis, E Hitron, H Collins, EC Judson, OB Alese, R Donald Harvey, JW Carlisle	12/11/2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer	AK Nooka, AD Cohen, HC Lee, A Badros, A Suvannasankha, N Callander, AO Abdallah, S Trudel, A Chari, EN Libby, M Chaudhry, M Hultcrantz, KM Kortüm, R Popat, D Sborov, S Hakim, E Lewis, B Gorsh, B Bhushan, A McKeown, I Gupta, J Opalinska, PG Richardson, S Lonial	12/01/2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clinical cancer research : an official journal of the American Association for Cancer Research	DJ Chung, N Shah, J Wu, B Logan, L Bisharat, N Callander, G Cheloni, K Anderson, T Chodon, B Dhakal, S Devine, P Somaiya Dutt, Y Efebera, N Geller, H Ghiasuddin, P Hematti, L Holmberg, A Howard, B Johnson, D Karagkouni, HM Lazarus, E Malek, P McCarthy, D McKenna, A Mendizabal, A Nooka, N Munshi, L O'Donnell, AP Rapoport, J Reese, J Rosenblatt, R Soiffer, D Stroopinsky, L Uhl, IS Vlachos, EK Waller, JW Young, MC Pasquini, D Avigan	12/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	09/21/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	09/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	08/22/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	08/01/2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer	TG Martin, MV Mateos, A Nooka, A Banerjee, R Kobos, L Pei, M Qi, R Verona, M Doyle, J Smit, W Sun, D Trancucci, C Uhlar, NWCJ van de Donk, C Rodriguez	07/01/2023
Cardiotoxicities of Cellular Therapies: A Practical Approach in a Sea of Uncertainty. JCO oncology practice	A Mandawat, AK Nooka	06/01/2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of comparative effectiveness research	A Krishnan, AK Nooka, A Chari, AL Garfall, TG Martin, S Nair, X Lin, K Qi, A Londhe, L Pei, E Ammann, R Kobos, J Smit, T Parekh, A Marshall, M Slavcev, SZ Usmani	06/01/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	03/01/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	02/20/2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer research communications	A Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, AA McCook-Veal, JM Switchenko, M Saini, RM Valanparambil, KA Blum, PB Allen, MJ Lechowicz, JT Romancik, A Ayers, A Leal, CB O'Leary, MC Churnetski, K Baird, M Kives, J Wrammert, AK Nooka, JL Koff, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	12/01/2022
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future oncology (London, England)	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PG Richardson, P Voorhees	12/01/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	11/20/2022
EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	10/01/2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. Science advances	A Sharma, R Nair, A Achreja, A Mittal, P Gupta, K Balakrishnan, CL Edgar, O Animasahun, B Dwivedi, BG Barwick, VA Gupta, SM Matulis, M Bhasin, S Lonial, AK Nooka, AP Wiita, LH Boise, D Nagrath, M Shanmugam	09/30/2022
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia	A Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, R Valanparambil, K Blum, P Allen, M Lechowicz, J Romancik, A Ayers, C O'Leary, M Churnetski, M Kives, A Nooka, J Koff, M Dhodapkar, M Suthar, J Cohen, R Ahmed	09/27/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	09/10/2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Chang, A Akhtar, SL Linderman, L Lai, VM Orellana-Noia, R Valanparambil, H Ahmed, VI Zarnitsyna, AA McCook-Veal, JM Switchenko, JL Koff, KA Blum, AA Ayers, CB O'Leary, MC Churnetski, S Sulaiman, M Kives, P Sheng, CW Davis, AK Nooka, R Antia, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	09/10/2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica	R Nair, V Subramaniam, BG Barwick, VA Gupta, SM Matulis, S Lonial, LH Boise, AK Nooka, K Muthumalaiappan, M Shanmugam	09/01/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	08/04/2022
Carfilzomib 56 mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia & lymphoma	K Weisel, AK Nooka, E Terpos, A Spencer, H Goldschmidt, F Dirnberger, L DeCosta, A Yusuf, S Kumar	08/01/2022
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion	EL Snyder, AP Wheeler, M Refaai, CS Cohn, J Poisson, M Fontaine, M Sehl, AK Nooka, L Uhl, P Spinella, M Fenelus, D Liles, T Coyle, J Becker, M Jeng, EA Gehrie, BR Spencer, P Young, A Johnson, JJ O'Brien, GJ Schiller, JD Roback, E Malynn, R Jackups, ST Avecilla, JS Lin, K Liu, S Bentow, HL Peng, J Varrone, RJ Benjamin, LM Corash	07/01/2022
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood cancer journal	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, JB Bartlett, J Vermeulen, TS Lin, PG Richardson, P Voorhees	04/13/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	03/01/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	02/01/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern. medRxiv : the preprint server for health sciences	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	01/23/2022
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. The Lancet. Oncology	SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, K Weisel, M Gavriatopoulou, A Oriol, N Rabin, A Nooka, M Qi, M Beksac, A Jakubowiak, B Ding, A Zahlten-Kumeli, A Yusuf, M Dimopoulos	01/01/2022
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. Cancer	AK Nooka, NS Joseph, S Lonial	11/15/2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, D Sborov, A Suvannasankha, K Weisel, PM Voorhees, L Womersley, J Baron, T Piontek, E Lewis, J Opalinska, I Gupta, AD Cohen	11/15/2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	11/01/2021
Selinexor for the treatment of patients with previously treated multiple myeloma. Expert review of hematology	CC Mo, S Jagannath, A Chari, AK Nooka, S Lonial, D Siegel, N Biran, C Gasparetto, NJ Bahlis, P Richardson	08/01/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	07/01/2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood cancer journal	S Jagannath, Y Lin, H Goldschmidt, D Reece, A Nooka, A Senin, P Rodriguez-Otero, R Powles, K Matsue, N Shah, LD Anderson, M Streetly, K Wilson, HV Le, AS Swern, A Agarwal, DS Siegel	06/18/2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, KN Conneely, YC Lin, CC Hofmeister, AK Nooka, JJ Keats, S Lonial, PM Vertino, LH Boise	06/01/2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood cancer journal	S Lonial, AK Nooka, P Thulasi, AZ Badros, BH Jeng, NS Callander, HA Potter, D Sborov, BE Zaugg, R Popat, S Degli Esposti, J Byrne, J Opalinska, J Baron, T Piontek, I Gupta, R Dana, AV Farooq, K Colby, A Jakubowiak	05/26/2021
Maintenance Strategies for Myeloma: Is Bigger Always Better? Cancer journal (Sudbury, Mass.)	AK Nooka, NS Joseph	05/01/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	03/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	12/14/2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JL Kaufman, R Mina, JJ Shah, JP Laubach, AK Nooka, C Lewis, C Gleason, C Sharp, RD Harvey, LT Heffner, P Richardson, S Lonial, RZ Orlowski	12/01/2020
Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia & lymphoma	A Jurczyszyn, A Waszczuk-Gajda, JJ Castillo, K Krawczyk, M Stork, L Pour, L Usnarska-Zubkiewicz, S Potoczek, I Hus, J Davila Valls, P Hari, S Chhabra, M Gentile, G Mikala, G Varga, CS Chim, M Fiala, R Vij, N Schutz, M Rodzaj, A Porowska, DH Vesole, A Druzd-Sitek, J Walewski, AK Nooka	12/01/2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	12/01/2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	12/01/2020
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO oncology practice	Y Yu, N Brown Wade, AE Hwang, AK Nooka, MA Fiala, A Mohrbacher, ES Peters, K Pawlish, C Bock, DJ Van Den Berg, KA Rand, D Stram, DV Conti, D Auclair, GA Colditz, J Mehta, CA Haiman, H Terebelo, N Janakiraman, S Singhal, B Chiu, R Vij, L Bernal-Mizrachi, JA Zonder, CA Huff, S Lonial, RZ Orlowski, W Cozen, S Ailawadhi	10/01/2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia	M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, D Dingli, RF Cornell, CC Hofmeister, D Siegel, JG Berdeja, D Reece, D White, S Lentzsch, C Gasparetto, CA Huff, S Jagannath, R Baz, AK Nooka, J Richter, R Abonour, TL Parker, AJ Yee, P Moreau, S Lonial, S Tuchman, KC Weisel, M Mohty, S Choquet, TJ Unger, K Li, Y Chai, L Li, J Shah, S Shacham, MG Kauffman, MA Dimopoulos	09/01/2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of hematology & oncology	K Weisel, A Spencer, S Lentzsch, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, A Nooka, H Quach, M Munder, C Lee, W Barreto, P Corradini, CK Min, AA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, JC Jo, HJ Shin, P Sonneveld, T Casneuf, N DeAngelis, H Amin, J Ukropec, R Kobos, MV Mateos	08/20/2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical lymphoma, myeloma & leukemia	MV Mateos, P Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, P Corradini, CK Min, E Medvedova, K Weisel, C Chiu, JM Schecter, H Amin, X Qin, J Ukropec, R Kobos, A Spencer	08/01/2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for immunotherapy of cancer	N Shah, J Aiello, DE Avigan, JG Berdeja, IM Borrello, A Chari, AD Cohen, K Ganapathi, L Gray, D Green, A Krishnan, Y Lin, E Manasanch, NC Munshi, AK Nooka, AP Rapoport, EL Smith, R Vij, M Dhodapkar	07/01/2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI insight	N Bar, F Costa, R Das, A Duffy, M Samur, S McCachren, SN Gettinger, N Neparidze, TL Parker, JK Bailur, K Pendleton, R Bajpai, L Zhang, ML Xu, T Anderson, N Giuliani, A Nooka, HJ Cho, A Raval, M Shanmugam, KM Dhodapkar, MV Dhodapkar	06/18/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	06/10/2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clinical lymphoma, myeloma & leukemia	J Mikhael, KR Noonan, B Faiman, C Gleason, AK Nooka, LJ Costa, S Jagannath, PG Richardson, D Siegel, A Chari, S Lentzch	06/01/2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood cancer journal	R Mina, NS Joseph, F Gay, E Kastritis, MT Petrucci, JL Kaufman, V Montefusco, M Gavriatopoulou, F Patriarca, P Omedé, LH Boise, M Roussou, N Giuliani, S Oliva, M Offidani, A Belotti, DL Jaye, L De Paoli, E Terpos, S Lonial, M Boccadoro, AK Nooka, MA Dimopoulos	04/14/2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature communications	R Bajpai, A Sharma, A Achreja, CL Edgar, C Wei, AA Siddiqa, VA Gupta, SM Matulis, SK McBrayer, A Mittal, M Rupji, BG Barwick, S Lonial, AK Nooka, LH Boise, D Nagrath, M Shanmugam	03/06/2020
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet. Oncology	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, N Lendvai, D Sborov, A Suvannasankha, K Weisel, L Karlin, E Libby, B Arnulf, T Facon, C Hulin, KM Kortüm, P Rodríguez-Otero, SZ Usmani, P Hari, R Baz, H Quach, P Moreau, PM Voorhees, I Gupta, A Hoos, E Zhi, J Baron, T Piontek, E Lewis, RC Jewell, EJ Dettman, R Popat, SD Esposti, J Opalinska, P Richardson, AD Cohen	02/01/2020
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances	Z Du, N Weinhold, GC Song, KA Rand, DJ Van Den Berg, AE Hwang, X Sheng, V Hom, S Ailawadhi, AK Nooka, S Singhal, K Pawlish, ES Peters, C Bock, A Mohrbacher, A Stram, SI Berndt, WJ Blot, G Casey, VL Stevens, R Kittles, PJ Goodman, WR Diver, A Hennis, B Nemesure, EA Klein, BA Rybicki, JL Stanford, JS Witte, L Signorello, EM John, L Bernstein, AM Stroup, OW Stephens, M Zangari, F Van Rhee, A Olshan, W Zheng, JJ Hu, R Ziegler, SJ Nyante, SA Ingles, MF Press, JD Carpten, SJ Chanock, J Mehta, GA Colditz, J Wolf, TG Martin, M Tomasson, MA Fiala, H Terebelo, N Janakiraman, L Kolonel, KC Anderson, L Le Marchand, D Auclair, BC Chiu, E Ziv, D Stram, R Vij, L Bernal-Mizrachi, GJ Morgan, JA Zonder, CA Huff, S Lonial, RZ Orlowski, DV Conti, CA Haiman, W Cozen	01/14/2020
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica	MV Mateos, A Spencer, AK Nooka, L Pour, K Weisel, M Cavo, JP Laubach, G Cook, S Iida, L Benboubker, SZ Usmani, SS Yoon, NJ Bahlis, C Chiu, J Ukropec, JM Schecter, X Qin, L O'Rourke, MA Dimopoulos	01/01/2020
Approaches to Treating Multiple Myeloma, Now and Moving Forward. JCO oncology practice	VA Gupta, NS Joseph, AK Nooka	01/01/2020
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	11/25/2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer	AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, LH Boise, S Lonial	09/01/2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England journal of medicine	A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, P Moreau, D Dingli, C Cole, S Lonial, M Dimopoulos, AK Stewart, J Richter, R Vij, S Tuchman, MS Raab, KC Weisel, M Delforge, RF Cornell, D Kaminetzky, JE Hoffman, LJ Costa, TL Parker, M Levy, M Schreder, N Meuleman, L Frenzel, M Mohty, S Choquet, G Schiller, RL Comenzo, M Engelhardt, T Illmer, P Vlummens, C Doyen, T Facon, L Karlin, A Perrot, K Podar, MG Kauffman, S Shacham, L Li, S Tang, C Picklesimer, JR Saint-Martin, M Crochiere, H Chang, S Parekh, Y Landesman, J Shah, PG Richardson, S Jagannath	08/22/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	07/15/2019
Registering a CD38 antibody upfront for multiple myeloma. Lancet (London, England)	CC Hofmeister, A Nooka, JL Kaufman, S Lonial	07/06/2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia	SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, LT Heffner, S Lonial, AK Nooka, JL Kaufman, LH Boise	05/01/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	04/23/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	04/23/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	02/01/2019
Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer	NS Joseph, JL Kaufman, LH Boise, K Valla, DK Almaula, CO Obidike, AA Langston, EK Waller, HJ Khoury, CR Flowers, M Graiser, LT Heffner, S Lonial, AK Nooka	01/15/2019
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	KM Mullane, DJ Winston, A Nooka, MI Morris, P Stiff, MJ Dugan, H Holland, K Gregg, JA Adachi, SA Pergam, BD Alexander, ER Dubberke, N Broyde, SL Gorbach, PS Sears	01/07/2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal	JL Kaufman, R Mina, AJ Jakubowiak, TL Zimmerman, JJ Wolf, C Lewis, C Gleason, C Sharp, T Martin, LT Heffner, AK Nooka, RD Harvey, S Lonial	01/04/2019
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer journal (Sudbury, Mass.)	AK Nooka, S Lonial	01/01/2019
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature communications	AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, J Cidado, KJ Embrey, E Gangl, FD Gibbons, GP Gregory, D Hargreaves, JA Hendricks, JW Johannes, RW Johnstone, SL Kazmirski, JG Kettle, ML Lamb, SM Matulis, AK Nooka, MJ Packer, B Peng, PB Rawlins, DW Robbins, AG Schuller, N Su, W Yang, Q Ye, X Zheng, JP Secrist, EA Clark, DM Wilson, SE Fawell, AW Hird	12/17/2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future oncology (London, England)	S Chehab, EH Panjic, C Gleason, S Lonial, AK Nooka	12/01/2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica	A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, AK Nooka, H Quach, C Lee, W Barreto, P Corradini, CK Min, EC Scott, AA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, JC Jo, HJ Shin, P Sonneveld, D Soong, T Casneuf, C Chiu, H Amin, M Qi, P Thiyagarajah, AK Sasser, JM Schecter, MV Mateos	12/01/2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA oncology	AK Nooka, ML Wang, AJ Yee, JL Kaufman, J Bae, D Peterkin, PG Richardson, NS Raje	12/01/2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer	S Chehab, C Zhang, EH Panjic, Z Chen, JL Kaufman, S Lonial, A Nooka, RD Harvey	11/15/2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer	A Chari, S Lonial, TM Mark, AY Krishnan, KE Stockerl-Goldstein, SZ Usmani, A Londhe, D Etheredge, S Fleming, B Liu, J Ukropec, TS Lin, S Jagannath, AK Nooka	11/15/2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of oncology practice	A Chang, TH Nasti, MK Khan, S Parashar, JL Kaufman, LH Boise, S Lonial, R Ahmed, AK Nooka	09/01/2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. Journal of oncology practice	AK Nooka, C Gleason, MO Sargeant, M Walker, M Watson, EH Panjic, S Lonial	07/01/2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, R Baz, A Nooka, J Richter, C Cole, R Vij, A Jakubowiak, R Abonour, G Schiller, TL Parker, LJ Costa, D Kaminetzky, JE Hoffman, AJ Yee, A Chari, D Siegel, R Fonseca, S Van Wier, G Ahmann, I Lopez, M Kauffman, S Shacham, JR Saint-Martin, CD Picklesimer, C Choe-Juliak, AK Stewart	03/20/2018
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia	Y Gu, K Xu, C Torre, M Samur, BG Barwick, M Rupji, J Arora, P Neri, J Kaufman, A Nooka, L Bernal-Mizrachi, P Vertino, SY Sun, J Chen, N Munshi, H Fu, J Kowalski, LH Boise, S Lonial	03/01/2018
CD86 regulates myeloma cell survival. Blood advances	CM Gavile, BG Barwick, S Newman, P Neri, AK Nooka, S Lonial, KP Lee, LH Boise	11/28/2017
Development of GLUT4-selective antagonists for multiple myeloma therapy. European journal of medicinal chemistry	C Wei, R Bajpai, H Sharma, M Heitmeier, AD Jain, SM Matulis, AK Nooka, RK Mishra, PW Hruz, GE Schiltz, M Shanmugam	10/20/2017
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood advances	SP Shah, AK Nooka, S Lonial, LH Boise	09/26/2017
High-risk Multiple Myeloma: Definition and Management. Clinical lymphoma, myeloma & leukemia	NS Joseph, S Gentili, JL Kaufman, S Lonial, AK Nooka	07/01/2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood	HC Sullivan, C Gerner-Smidt, AK Nooka, CM Arthur, L Thompson, A Mener, SR Patel, M Yee, RM Fasano, CD Josephson, RM Kaufman, JD Roback, S Lonial, SR Stowell	06/01/2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infection control and hospital epidemiology	NN Shah, W McClellan, CR Flowers, S Lonial, H Khoury, EK Waller, A Langston, AK Nooka	06/01/2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood	VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, S Lonial, LH Boise	04/06/2017
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone marrow transplantation	Z DeFilipp, CB Rosand, DA Goldstein, VA Master, BC Carthon, WB Harris, O Kucuk, Z Al-Kadhimi, JB Cohen, CR Flowers, MJ Lechowicz, AK Nooka, JL Kaufman, AA Langston, Z Chen, J Arora, EK Waller	01/01/2017
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	KA Rand, C Song, E Dean, DJ Serie, K Curtin, X Sheng, D Hu, CA Huff, L Bernal-Mizrachi, MH Tomasson, S Ailawadhi, S Singhal, K Pawlish, ES Peters, CH Bock, A Stram, DJ Van Den Berg, CK Edlund, DV Conti, T Zimmerman, AE Hwang, S Huntsman, J Graff, A Nooka, Y Kong, SL Pregja, SI Berndt, WJ Blot, J Carpten, G Casey, L Chu, WR Diver, VL Stevens, MR Lieber, PJ Goodman, AJ Hennis, AW Hsing, J Mehta, RA Kittles, S Kolb, EA Klein, C Leske, AB Murphy, B Nemesure, C Neslund-Dudas, SS Strom, R Vij, BA Rybicki, JL Stanford, LB Signorello, JS Witte, CB Ambrosone, P Bhatti, EM John, L Bernstein, W Zheng, AF Olshan, JJ Hu, RG Ziegler, SJ Nyante, EV Bandera, BM Birmann, SA Ingles, MF Press, D Atanackovic, MJ Glenn, LA Cannon-Albright, B Jones, G Tricot, TG Martin, SK Kumar, JL Wolf, SL Deming Halverson, N Rothman, AR Brooks-Wilson, SV Rajkumar, LN Kolonel, SJ Chanock, SL Slager, RK Severson, N Janakiraman, HR Terebelo, EE Brown, AJ De Roos, AF Mohrbacher, GA Colditz, GG Giles, JJ Spinelli, BC Chiu, NC Munshi, KC Anderson, J Levy, JA Zonder, RZ Orlowski, S Lonial, NJ Camp, CM Vachon, E Ziv, DO Stram, DJ Hazelett, CA Haiman, W Cozen	12/01/2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer	AK Nooka, M Behera, S Lonial, MD Dixon, SS Ramalingam, RD Pentz	10/15/2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget	SP Shah, AK Nooka, DL Jaye, NJ Bahlis, S Lonial, LH Boise	09/13/2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia & lymphoma	A Jurczyszyn, M Olszewska-Szopa, V Hungria, E Crusoe, T Pika, M Delforge, X Leleu, L Rasche, AK Nooka, A Druzd-Sitek, J Walewski, J Davila, J Caers, V Maisnar, M Gertz, M Gentile, D Fantl, G Mele, DH Vesole, AJ Yee, C Shustik, S Lentzsch, S Zweegman, A Gozzetti, AB Skotnicki, JJ Castillo	09/01/2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. The New England journal of medicine	A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, I Spicka, V Hungria, M Munder, MV Mateos, TM Mark, M Qi, J Schecter, H Amin, X Qin, W Deraedt, T Ahmadi, A Spencer, P Sonneveld	08/25/2016
Is Maintenance Therapy for Everyone? Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	08/01/2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer biology & therapy	KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, AK Nooka, JL Kaufman, S Lonial, LH Boise	07/02/2016
Death by a thousand cuts: the slow demise of chemotherapy. Cancer	AK Nooka, S Lonial	07/01/2016
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American journal of hematology	A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, E Crusoe, AL Silva Dias, R Vij, MA Fiala, J Caers, L Rasche, AK Nooka, S Lonial, DH Vesole, S Philip, S Gangatharan, A Druzd-Sitek, J Walewski, A Corso, F Cocito, MC Vekemans, E Atilla, M Beksac, X Leleu, J Davila, A Badros, E Aneja, N Abildgaard, E Kastritis, D Fantl, N Schutz, T Pika, A Butrym, M Olszewska-Szopa, L Usnarska-Zubkiewicz, SZ Usmani, H Nahi, CS Chim, C Shustik, K Madry, S Lentzsch, A Swiderska, G Helbig, R Guzicka-Kazimierczak, N Lendvai, A Waage, KT Andersen, H Murakami, S Zweegman, JJ Castillo	06/01/2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget	J Deng, D Park, M Wang, A Nooka, Q Deng, S Matulis, J Kaufman, S Lonial, LH Boise, J Galipeau, X Deng	05/10/2016
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia	SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, LH Boise	05/01/2016
Novel Combination Treatments in Multiple Myeloma. Oncology (Williston Park, N.Y.)	AK Nooka, S Lonial	05/01/2016
Myeloma Is Not a Single Disease. Journal of oncology practice	S Lonial, AK Nooka	04/01/2016
Meningeal Myelomatosis. Journal of oncology practice	Z DeFilipp, EA Sahovic, AK Nooka	02/01/2016
New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	AK Nooka, S Lonial	01/01/2016
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. Journal of stem cell research & therapy	HD Yun, T Dossul, L Bernal-Mizrachi, J Switchenko, C Ndibe, A Ibraheem, MD Dixon, AA Langston, AK Nooka, CR Flowers, RD Pentz, EK Waller	01/01/2016
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park, N.Y.)	AK Nooka	12/01/2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology	AO Kaseb, M Shama, IH Sahin, A Nooka, HM Hassabo, JN Vauthey, T Aloia, JL Abbruzzese, IM Subbiah, F Janku, S Curley, MM Hassan	01/01/2013
Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease. Current drug delivery	E Reid, A Nooka, J Blackmon, MJ Lechowicz	01/01/2012
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research	AO Hoff, BB Toth, K Altundag, MM Johnson, CL Warneke, M Hu, A Nooka, G Sayegh, V Guarneri, K Desrouleaux, J Cui, A Adamus, RF Gagel, GN Hortobagyi	06/01/2008

Awards

Multiple Myeloma Research Foundation
International Myeloma Foundation (IMF) Special Research Grant, 2014
Multiple Myeloma Research Foundation (MMRF) Accelerator Award, 2013
Conquer Foundation ASCO Merit Award, Chicago, IL, 2011
Fellowship of American College of Physicians, 2011
AACR/ASCO Workshop: Methods in Clinical Cancer Research, Vail, CO, 2010
Frederick C. Whittier Excellence in Research Award, Canton Medical Education Foundation, OH, 2008
Rochfort Scholarship, Emory University, GA, 2008
Frederick C. Whittier Excellence in Research Award, Canton Medical Education Foundation, OH, 2007
American College of Physicians National Abstracts Competition, San Diego, CA, 2007
D. Jack Kilian Memorial Scholarship, UTSPH, Houston, TX, 2003

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	04/12/2025	This is a GOOD MDHE showed me my labs comparing them to earlier months/ years while explaining them to me. Praise God for him
One star One star One star One star One star	04/01/2025	Great visit.
One star One star One star One star One star	03/25/2025	Great attitude. Smiling face. Patience with my asking questions. Communications
One star One star One star One star One star	03/25/2025	Very good
One star One star One star One star One star	03/10/2025	He is fantastic.
One star One star One star One star One star	02/11/2025	Good
One star One star One star One star One star	01/30/2025	Dr. Nooka is very attentive and he spent a lot of time answering my questions.
One star One star One star One star One star	01/11/2025	Dr. Nooka is the best!! Explains complex in a way that's easy to understand. He's very patient,compassionate and honest. He's a excellent asset to Emory.
One star One star One star One star One star	01/09/2025	Dr Nooka is an amazing doctor and kind person.
One star One star One star One star One star	01/07/2025	Dr Nooka is extremely knowledgeable and explains everything so I can understand.
One star One star One star One star One star	01/06/2025	Dr Nooka is patient, caring and knowledgeable. He is extremely through in his explanation. He has been consistently exceptional in providing me with professional care. Dr. Nooka is the best oncologist I could ever have because he informs me and my family of all the options for a longer life regarding my current cancer status. He is a better doctor than ever have.
One star One star One star One star One star	12/30/2024	My Provider, Ajay Nooka showed sincere concern for me, my daughters and condition. Dr. Nooka put thought and care with his team when planning for my after care of Multiple myeloma. Decisions for my care was made with careful consideration for my condition. Doctor Nooka explained my test results and took the time to go through every test results explaining what they showed and gave detailed simple feedback of each. He described aftercare treatment concerning medication to be taken, how and when and length of time. We discussed aftercare follow up plans. Doctor Nooka is an outstanding physician and an expert in his field as I'm sure you know already, and he is by far a wonderful human being that brings so much hope and passion to his patients working together with them for a good outcome! Meeting Doctor Nooka for the first time and listening to him explain my diagnosis of Multiple myeloma was encouraging and frightening at the same time but Dr. Nooka assured me that with my 100% cooperation we could have a positive outcome as a team and knew at that moment God was in the mist and Dr. Nooka did what he does for All of his patients, He went to work with his team to bring about an outcome I prayed and hope for. And that's to be cancer free and to recover my kidney function. Thank you Dr. Nooka and your amazing team of nurses, staff and social workers at Emory
One star One star One star One star One star	12/26/2024	Dr. Nooka has been monitoring a diagnosis of MGUS low risk since 2021. He Is the ONLY CURRENT EMORY Physician In whom I have the GREATEST CONFIDENCE AND FOR WHOM I HAVE THE GREATEST RESPECT.IN 2025, DR. NOOKA WILL MORE THAN LIKELY BE MY ONLY PHYSICIAN AT EMORY.I NO LONGER FEEL THAT EMORY IS ADDRESSING MY HEALTHCARE NEEDS AS AGE.
One star One star One star One star One star	12/23/2024	Dr. Nooka is the best!
One star One star One star One star One star	12/03/2024	Dr. Nooka is patient, caring and explains his reasoning.
One star One star One star One star One star	11/07/2024	I appreciated that Dr. Nooka reached out once he recognized that our planned appointment was impacted. He has always been very professional, patient, and answers my questions honestly. I ask alot of questions :)
One star One star One star One star One star	11/01/2024	Dr. Nooka is awesome.
One star One star One star One star One star	10/27/2024	The care Dr Nooka and Emory gave me is wonderful!
One star One star One star One star One star	10/23/2024	Emory has blown me and my family (and my nurse practitioner daughter!) away with the quality of expert care while still paying attention to how the patient is treated as a person. Patient-centered care where the patient is fully informed and educated and can ask any questions with thorough, appropriate level education, means so much and is unfortunately uncommon in some institutions of healthcare, but I've found it to be the norm and standard at Emory, and I can't speak highly enough of Dr. Nooka and his team! Theresa Brannon and the nurse (or assistant) Olivia who helped me into my room excelled in the care and empathy and information they provided me, and I know this impacted my entire experience in such a positive way!
One star One star One star One star One star	10/21/2024	Dr. Nooka is extremely thorough in his explanations.
One star One star One star One star One star	10/19/2024	Dr. Nookah took his time explaining everything to me. I was very impressed with him!
One star One star One star One star One star	09/26/2024	Dr. Nooka and his team provided me with clear oral, and written information and gave me the opportunity to ask questions.
One star One star One star One star One star	09/08/2024	Very good visit. Thanks
One star One star One star One star One star	08/29/2024	Dr. Nooka is wonderful. He helped me with the testing and other medical things, but at this point in my journey I needed to mentally feel better and he did just that. He is a very knowledgeable man and I'm thankful I got in with him.
One star One star One star One star One star	08/24/2024	Dr. Nooka is a very compassionate professional.
One star One star One star One star One star	08/23/2024	Dr Nooka is awesome
One star One star One star One star One star	08/23/2024	Fabulous
One star One star One star One star One star	08/21/2024	Dr Nooka is the best
One star One star One star One star One star	08/20/2024	He cares about you, has patience, and he's smart!
One star One star One star One star One star	08/19/2024	These apply to Dr Nooka. Very caring and compassionate. A wonderful man.
One star One star One star One star One star	08/19/2024	So very thankful Dr Nooka is my Doctor
One star One star One star One star One star	08/10/2024	Dr. Nooka shows great compassion and care! I trust him to do whatever is best for me. I would definitely recommend him.
One star One star One star One star One star	08/08/2024	Dr. Nooka has been consistently exceptional in providing me with professional care concerning my multiple myeloma since December 2018, when he evaluated me for a stem cell transplant. He has been thorough, comforting, supportive, and very clear on the reality of this disease.
One star One star One star One star One star	07/30/2024	Dr. Nooka is the best. He has been a great care provider to me for the last 9 years. I am beyond lucky to have him on my team.
One star One star One star One star One star	07/22/2024	Knowledgeable on multiple Myeloma with lastest studies and medicines
One star One star One star One star One star	07/20/2024	Dr.Nooka It's very professional and makes me feel very much at ease that his area of expertise and care for me is very much under control. He engenders trust. And is even very likable and a pleasure to deal with. Great bedside manner!
One star One star One star One star One star	07/16/2024	Good
One star One star One star One star One star	07/16/2024	Wonderful doctor.
One star One star One star One star One star	07/09/2024	Dr. Ajay Nooka is fantastic!
One star One star One star One star One star	07/06/2024	I was very pleased with the level of care I received. Was very informative, understanding and patient with my questions and strive to make sure I understood my condition
One star One star One star One star One star	07/06/2024	Dr Nooka is awesome!
One star One star One star One star One star	07/03/2024	The doctor was clear about how the procedure for me would be conducted and offered an opportunity to ask questions.
One star One star One star One star One star	06/30/2024	Always very professional, helpful and kind.
One star One star One star One star One star	06/09/2024	Since I was recommended by Dr. Nooka in 2021 by Georgia Cancer Specialists, Dr, Nooka has always been professional, knowledgeable, honest upfront and direct to me and my family displaying great concern for my health. Dr. Nooka is the best oncologist I could ever have because he informs me and my family of all the opinions at Emory UH Winship Cancer for a better longer life regarding my current and future cancer status. If it weren't for Dr. Nooka BMT team and Emory UH I wouldn't be here today.
One star One star One star One star One star	06/05/2024	He explained everything to the point that I truly understood. Used everyday scenarios. I was able to meet team members and learn from them too
One star One star One star One star One star	06/04/2024	You good not find a better Doctor than the one I have.
One star One star One star One star One star	06/04/2024	Very willing to answer questions
One star One star One star One star One star	06/04/2024	Excellent visit.
One star One star One star One star One star	05/31/2024	He described my options very clearly and in terms that I understood.
One star One star One star One star One star	05/27/2024	All wonderful
One star One star One star One star One star	05/25/2024	Dr Nooka is one of the best!
One star One star One star One star One star	05/25/2024	Dr Nooka, Maggie Hardin are very helpful and understanding of my concerns. They address my questions and offer me solutions. I feel that am in very good hands.
One star One star One star One star One star	05/24/2024	Dr. Noka was very thorough in his explanations and drew illustrations and tables to make things even more clear. I came away with a sense of complete confidence in him.
One star One star One star One star One star	05/24/2024	Dr. Nooka is very knowledgeable in his work, he and his team took good care of me.